X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ASTRAZENECA PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ASTRAZENECA PHARMA ABBOTT INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 35.4 92.1 38.5% View Chart
P/BV x 9.2 25.7 35.7% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
ASTRAZENECA PHARMA
Mar-14
ABBOTT INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1101,285 475.5%   
Low Rs3,996634 630.3%   
Sales per share (Unadj.) Rs1,552.2189.6 818.7%  
Earnings per share (Unadj.) Rs188.8-0.2 -92,733.2%  
Cash flow per share (Unadj.) Rs196.43.8 5,109.3%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.668.6 1,160.5%  
Shares outstanding (eoy) m21.2525.00 85.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.35.1 64.3%   
Avg P/E ratio x26.8-4,712.7 -0.6%  
P/CF ratio (eoy) x25.7249.6 10.3%  
Price / Book Value ratio x6.314.0 45.4%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,37623,988 447.6%   
No. of employees `0003.31.6 213.1%   
Total wages/salary Rs m3,9371,605 245.4%   
Avg. sales/employee Rs Th9,929.33,040.2 326.6%   
Avg. wages/employee Rs Th1,185.11,029.2 115.1%   
Avg. net profit/employee Rs Th1,207.7-3.3 -36,991.4%   
INCOME DATA
Net Sales Rs m32,9854,740 695.9%  
Other income Rs m1,17092 1,270.2%   
Total revenues Rs m34,1554,832 706.9%   
Gross profit Rs m5,245-130 -4,040.8%  
Depreciation Rs m162101 160.0%   
Interest Rs m380-   
Profit before tax Rs m6,215-139 -4,474.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m2,2035 43,275.0%   
Profit after tax Rs m4,012-5 -78,823.2%  
Gross profit margin %15.9-2.7 -580.6%  
Effective tax rate %35.4-3.7 -967.2%   
Net profit margin %12.2-0.1 -11,326.3%  
BALANCE SHEET DATA
Current assets Rs m22,6552,726 830.9%   
Current liabilities Rs m6,6812,435 274.4%   
Net working cap to sales %48.46.1 787.7%  
Current ratio x3.41.1 302.9%  
Inventory Days Days6574 87.8%  
Debtors Days Days2941 71.5%  
Net fixed assets Rs m8351,035 80.7%   
Share capital Rs m21350 425.0%   
"Free" reserves Rs m16,715942 1,773.7%   
Net worth Rs m16,9281,716 986.5%   
Long term debt Rs m00-   
Total assets Rs m24,1624,156 581.4%  
Interest coverage x163.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.41.1 119.7%   
Return on assets %16.8-0.1 -13,687.2%  
Return on equity %23.7-0.3 -7,990.5%  
Return on capital %36.90-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m369375 98.4%   
Fx outflow Rs m3,807470 809.7%   
Net fx Rs m-3,438-96 3,598.1%   
CASH FLOW
From Operations Rs m1,527-8 -18,851.9%  
From Investments Rs m-2,148-146 1,474.5%  
From Financial Activity Rs m-1,024862 -118.8%  
Net Cashflow Rs m-1,646709 -232.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 15.7 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 12,856 142.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 20, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS